Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage

Prostate

Volumn 71, Issue 8, 2011, Pages 824-834

  Gonzalez Moreno, Oscar ^a   Boque, Noemi ^b   Redrado, Miriam ^a   Milagro, Fermin ^b   Campion, Javier ^b   Endermann, Tobias ^c   Takahashi, Kazuhiko ^d   Saito, Yoshiro ^e   Catena, Raul ^a   Schomburg, Lutz ^c   Calvo, Alfonso ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^e DOSHISHA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FLUTAMIDE; HYDROGEN PEROXIDE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SELENOPROTEIN P;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CELL CULTURE; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PR 111 CELL LINE; PR 14 CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; TISSUE MICROARRAY;

ANDROGEN ANTAGONISTS; CARCINOMA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FLUTAMIDE; HUMANS; HYDROGEN PEROXIDE; MALE; OXIDATIVE STRESS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SELENOPROTEIN P;

EID: 79953719388     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21298     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118(10):793-803. (Pubitemid 23135479)
3. Zynger DL, Yang X. High-grade prostatic intraepithelial neoplasia of the prostate: The precursor lesion of prostate cancer. Int J Clin Exp Pathol 2009;2(4):327-338.
4. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ. Growth factors involved in prostate carcinogenesis. Front Biosci 2005;10:1355-1367.
5. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282(2):125-136.
6. Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension 2009;53(6):885-892.
7. Buffenstein R, Edrey YH, Yang T, Mele J. The oxidative stress theory of aging: Embattled or invincible? Insights from non-traditional model organisms. Age (Dordr) 2008;30(2-3):99-109.
8. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 2003;17(10):1195-1214. (Pubitemid 36775767)
9. Minelli A, Bellezza I, Conte C, Culig Z. Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta 2009;1795(2):83-91.
10. Bock A, Forchhammer K, Heider J, Baron C. Selenoprotein synthesis: An expansion of the genetic code. Trends Biochem Sci 1991;16(12):463-467.
11. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN. Characterization of mammalian selenoproteomes. Science 2003;300(5624):1439-1443. (Pubitemid 36638165)
12. Burk RF, Hill KE. Selenoprotein P: An extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 2005;25:215-235. (Pubitemid 41209001)
13. Schomburg L, Schweizer U, Holtmann B, Flohe L, Sendtner M, Kohrle J. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 2003;370(Pt 2):397-402. (Pubitemid 36315127)
14. Schmutzler C, Mentrup B, Schomburg L, Hoang-Vu C, Herzog V, Kohrle J. Selenoproteins of the thyroid gland: Expression, localization and possible function of glutathione peroxidase 3. Biol Chem 2007;388(10):1053-1059. (Pubitemid 47584302)
15. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE. Alterations in gene expression profiles during prostate cancer progression: Functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002;62(18):5325-5335. (Pubitemid 35024609)
16. Scharpf M, Schweizer U, Arzberger T, Roggendorf W, Schomburg L, Kohrle J. Neuronal and ependymal expression of selenoprotein P in the human brain. J Neural Transm 2007;114(7):877-884. (Pubitemid 47013589)
17. Saito Y, Takahashi K. Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem 2002;269(22):5746-5751. (Pubitemid 35365563)
18. Saito Y, Sato N, Hirashima M, Takebe G, Nagasawa S, Takahashi K. Domain structure of bi-functional selenoprotein P. Biochem J 2004;381(Pt 3):841-846. (Pubitemid 39120494)
19. Hill KE, Zhou J, McMahan WJ, Motley AK, Atkins JF, Gesteland RF, Burk RF. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 2003;278(16):13640-13646. (Pubitemid 36799899)
20. Steinbrenner H, Alili L, Bilgic E, Sies H, Brenneisen P. Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med 2006;40(9):1513-1523.
21. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mork H, Scheurlen M, Brigelius-Flohe R, Schottker K, Abel J, Thalheimer A, Katzenberger T, Illert B, Melcher R, Kohrle J. Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer 2004;48(1):6-14. (Pubitemid 38823541)
22. Gresner P, Gromadzinska J, Jablonska E, Kaczmarski J, Wasowicz W. Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung Cancer 2009;65(1):34-40.
23. Mostert V, Dreher I, Kohrle J, Wolff S, Abel J. Modulation of selenoprotein P expression by TGF-beta(1) is mediated by Smad proteins. Biofactors 2001;14(1-4):135-142.
24. Mostert V, Wolff S, Dreher I, Kohrle J, Abel J. Identification of an element within the promoter of human selenoprotein P responsive to transforming growth factor-beta. Eur J Biochem 2001;268(23):6176-6181. (Pubitemid 33132037)
25. Walter PL, Steinbrenner H, Barthel A, Klotz LO. Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor. Biochem Biophys Res Commun 2008;365(2):316-321. (Pubitemid 350137290)
26. Soares CR, Shibata MA, Green JE, Jorcyk CL. Development of PIN and prostate adenocarcinoma cell lines: A model system for multistage tumor progression. Neoplasia 2002;4(2):112-120. (Pubitemid 34218679)
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25(4):402-408. (Pubitemid 34164012)
28. Heo HY, Park JM, Kim CH, Han BS, Kim KS, Seol W. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 2010;316(4):649-656.
29. Olson GE, Winfrey VP, Nagdas SK, Hill KE, Burk RF. Apolipoprotein E receptor-2 (ApoER2) mediates selenium uptake from selenoprotein P by the mouse testis. J Biol Chem 2007;282(16):12290-12297. (Pubitemid 47100729)
30. Olson GE, Winfrey VP, Hill KE, Burk RF. Megalin mediates selenoprotein P uptake by kidney proximal tubule epithelial cells. J Biol Chem 2008;283(11):6854-6860.
31. Steinert P, Bachner D, Flohe L. Analysis of the mouse selenoprotein P gene. Biol Chem 1998;379(6):683-691. (Pubitemid 28327567)
32. Nishimura K, Matsumiya K, Tsujimura A, Koga M, Kitamura M, Okuyama A. Association of selenoprotein P with testosterone production in cultured Leydig cells. Arch Androl 2001;47(1):67-76. (Pubitemid 32579159)
33. Cross D, Reding DJ, Salzman SA, Zhang KQ, Catalona WJ, Burke J, Burmester JK. Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines. Med Oncol 2004;21(2):145-153.
34. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 2010;9(1):33-45.
35. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39(1):44-84. (Pubitemid 44566469)
36. Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008;10(11):1883-1894.
37. Moghadaszadeh B, Beggs AH. Selenoproteins and their impact on human health through diverse physiological pathways. Physiology (Bethesda) 2006;21:307-315. (Pubitemid 44511758)
38. Meyer HA, Hollenbach B, Stephan C, Endermann T, Morgenthaler NG, Cammann H, Kohrle J, Jung K, Schomburg L. Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2009;18(9):2386-2390.
39. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, Diamond AM, Gladyshev VN. Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 2000;275(45):35540-35547.
40. Burk RF, Hill KE, Boeglin ME, Ebner FF, Chittum HS. Selenoprotein P associates with endothelial cells in rat tissues. Histochem Cell Biol 1997;108(1):11-15. (Pubitemid 27321668)
41. Steinbrenner H, Bilgic E, Alili L, Sies H, Brenneisen P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res 2006;40(9):936-943. (Pubitemid 44480556)
42. Bruzelius K, Hoac T, Sundler R, Onning G, Akesson B. Occurrence of selenoprotein enzyme activities and mRNA in bovine mammary tissue. J Dairy Sci 2007;90(2):918-927. (Pubitemid 350049738)
43. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, Lantvit DL, Diamond AM. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci USA 2006;103(21):8179-8184. (Pubitemid 43801072)
44. Pathak S, Singh R, Verschoyle RD, Greaves P, Farmer PB, Steward WP, Mellon JK, Gescher AJ, Sharma RA. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett 2008;261(1):74-83.
45. Tsai SC, Lu CC, Lin CS, Wang PS. Antisteroidogenic actions of hydrogen peroxide on rat Leydig cells. J Cell Biochem 2003;90(6):1276-1286. (Pubitemid 37485061)
46. Yi YS, Park SG, Byeon SM, Kwon YG, Jung G. Hepatitis B virus X protein induces TNF-alpha expression via down-regulation of selenoprotein P in human hepatoma cell line, HepG2. Biochim Biophys Acta 2003;1638(3):249-256. (Pubitemid 37288963)
47. Bosschaerts T, Guilliams M, Noel W, Herin M, Burk RF, Hill KE, Brys L, Raes G, Ghassabeh GH, De Baetselier P, Beschin A. Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol 2008;180(9):6168- 6175.
48. Hollenbach B, Morgenthaler NG, Struck J, Alonso C, Bergmann A, Kohrle J, Schomburg L. New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol 2008;22(1):24-32.
49. Renko K, Hofmann PJ, Stoedter M, Hollenbach B, Behrends T, Kohrle J, Schweizer U, Schomburg L. Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. FASEB J 2009;23(6):1758-1765.
50. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K, Maehara Y, Selenoprotein P. as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 2004;112(2):184-189. (Pubitemid 39244357)
51. Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: Therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009;13(2):227-234.
52. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, van der Pluijm G. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 2007;24(8):609-617.
53. Girdhani S, Bhosle SM, Thulsidas SA, Kumar A, Mishra KP. Potential of radiosensitizing agents in cancer chemo-radiotherapy. J Cancer Res Ther 2005;1(3):129-131. (Pubitemid 43511063)
54. Greenberger JS, Kagan VE, Pearce L, Boriseniao G, Tyurina Y, Epperly MW. Modulation of redox signal transduction pathways in the treatment of cancer. Antioxid Redox Signal 2001;3(3):347-359. (Pubitemid 32646027)
55. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004;14(3):259-266. (Pubitemid 38903230)